American Trust Has $2.27 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

American Trust decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 18.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,059 shares of the biopharmaceutical company's stock after selling 6,167 shares during the quarter. American Trust's holdings in Gilead Sciences were worth $2,269,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of GILD. Avior Wealth Management LLC lifted its stake in shares of Gilead Sciences by 1.2% in the 3rd quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company's stock worth $782,000 after acquiring an additional 108 shares during the period. Concord Asset Management LLC VA boosted its stake in Gilead Sciences by 3.8% during the 3rd quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company's stock valued at $256,000 after purchasing an additional 111 shares in the last quarter. TFB Advisors LLC raised its stake in shares of Gilead Sciences by 1.2% in the 3rd quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company's stock worth $788,000 after buying an additional 116 shares in the last quarter. Sumitomo Life Insurance Co. lifted its holdings in shares of Gilead Sciences by 0.7% in the third quarter. Sumitomo Life Insurance Co. now owns 17,822 shares of the biopharmaceutical company's stock valued at $1,494,000 after buying an additional 117 shares during the period. Finally, FDx Advisors Inc. grew its holdings in Gilead Sciences by 2.2% during the third quarter. FDx Advisors Inc. now owns 5,365 shares of the biopharmaceutical company's stock worth $450,000 after acquiring an additional 117 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Stock Down 0.6 %

NASDAQ GILD traded down $0.52 during trading on Friday, reaching $91.86. The company's stock had a trading volume of 7,514,582 shares, compared to its average volume of 7,068,425. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The stock has a market capitalization of $114.48 billion, a PE ratio of 1,026.44, a PEG ratio of 2.38 and a beta of 0.18. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90. The business has a 50-day moving average price of $89.82 and a 200-day moving average price of $79.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts' consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm's revenue was up 7.0% compared to the same quarter last year. During the same period last year, the business earned $2.29 EPS. On average, research analysts forecast that Gilead Sciences, Inc. will post 4.35 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be paid a $0.77 dividend. The ex-dividend date is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.35%. Gilead Sciences's payout ratio is presently 3,422.22%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. UBS Group lifted their price objective on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a "neutral" rating in a research note on Thursday, November 21st. Oppenheimer upped their price target on Gilead Sciences from $105.00 to $115.00 and gave the company an "outperform" rating in a report on Tuesday. Royal Bank of Canada reissued a "sector perform" rating and set a $84.00 price objective on shares of Gilead Sciences in a research note on Wednesday. JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. Finally, Truist Financial increased their price target on Gilead Sciences from $83.00 to $97.00 and gave the company a "hold" rating in a research report on Friday, November 8th. Twelve research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences has a consensus rating of "Moderate Buy" and a consensus target price of $96.43.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of the business's stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the transaction, the insider now owns 100,189 shares of the company's stock, valued at approximately $8,398,843.87. The trade was a 1.96 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jeffrey Bluestone sold 6,788 shares of the firm's stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares in the company, valued at $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 447,234 shares of company stock worth $41,288,086 in the last quarter. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.